(NYSE: NVS) Novartis Ag's forecast annual revenue growth rate of 2.14% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 5.99%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.15%.
Novartis Ag's revenue in 2025 is $56,372,000,000.On average, 24 Wall Street analysts forecast NVS's revenue for 2025 to be $109,019,304,000,000, with the lowest NVS revenue forecast at $103,285,602,000,000, and the highest NVS revenue forecast at $117,218,286,000,000. On average, 24 Wall Street analysts forecast NVS's revenue for 2026 to be $111,912,156,000,000, with the lowest NVS revenue forecast at $102,272,526,000,000, and the highest NVS revenue forecast at $122,678,496,000,000.
In 2027, NVS is forecast to generate $115,879,716,000,000 in revenue, with the lowest revenue forecast at $97,582,716,000,000 and the highest revenue forecast at $127,713,060,000,000.